Linnea T. Olsson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linnea T. Olsson has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Melissa A. Troester
Department of Epidemiology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
50 shared publications - Erin L. Kirk
University of North Carolina at Chapel Hill 10 Chapel Hill, North Carolina
41 shared publications - Alina M. Hamilton
Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
29 shared publications - Amir Mahmoudzadeh
University of California, San Francisco, San Francisco, California
19 shared publications Jeff Wang
19 shared publications- Ruth M. Pfeiffer
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, USA
19 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients
Background:Immunotherapy is a rapidly evolving treatment option in breast cancer; However, the breast cancer immune microenvironment is understudied in Black and younger (<50 years) patients.Methods:We used histologic and RNA-based immunoprofiling methods to characterize the breast cancer immune landscape in 1,952 tumors from the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1,030) and young women (n = 1,039). We evaluated immune response leveraging markers for 10 immune cell populations, compared profiles to those in The Cancer Genome Atlas (TCGA) Project [n = 1,095 tumors, Black (n = 183), and young women (n = 295)], and evaluated in association with clinical and demographic variables, including recurrence.Results:Consensus clustering identified three immune clusters in CBCS (adaptive-enriched, innate-enriched, or immune-quiet) that varied in frequency by race, age, tumor grade and subtype; however, only two clusters were identified in TCGA, which were predominantly comprised of adaptive-enriched and innate-enriched tumors. In CBCS, the strongest adaptive immune response was observed for basal-like, HER2-positive (HER2+), triple-negative breast cancer (TNBC), and high-grade tumors. Younger patients had higher proportions of adaptive-enriched tumors, particularly among estrogen receptor (ER)-negative (ER−) cases. Black patients had higher frequencies of both adaptive-enriched and innate-enriched tumors. Immune clusters were associated with recurrence among ER− tumors, with adaptive-enriched showing the best and innate-enriched showing the poorest 5-year recurrence-free survival.Conclusions:These data suggest that immune microenvironments are intricately related to race, age, tumor subtype, and grade.Impact:Given higher mortality among Black and young women, more defined immune classification using cell-type–specific panels could help explain higher recurrence and ultimately lead to targetable interventions.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients
Background:Immunotherapy is a rapidly evolving treatment option in breast cancer; However, the breast cancer immune microenvironment is understudied in Black and younger (<50 years) patients.Methods:We used histologic and RNA-based immunoprofiling methods to characterize the breast cancer immune landscape in 1,952 tumors from the Carolina Breast Cancer Study (CBCS), a population-based study that oversampled Black (n = 1,030) and young women (n = 1,039). We evaluated immune response leveraging markers for 10 immune cell populations, compared profiles to those in The Cancer Genome Atlas (TCGA) Project [n = 1,095 tumors, Black (n = 183), and young women (n = 295)], and evaluated in association with clinical and demographic variables, including recurrence.Results:Consensus clustering identified three immune clusters in CBCS (adaptive-enriched, innate-enriched, or immune-quiet) that varied in frequency by race, age, tumor grade and subtype; however, only two clusters were identified in TCGA, which were predominantly comprised of adaptive-enriched and innate-enriched tumors. In CBCS, the strongest adaptive immune response was observed for basal-like, HER2-positive (HER2+), triple-negative breast cancer (TNBC), and high-grade tumors. Younger patients had higher proportions of adaptive-enriched tumors, particularly among estrogen receptor (ER)-negative (ER−) cases. Black patients had higher frequencies of both adaptive-enriched and innate-enriched tumors. Immune clusters were associated with recurrence among ER− tumors, with adaptive-enriched showing the best and innate-enriched showing the poorest 5-year recurrence-free survival.Conclusions:These data suggest that immune microenvironments are intricately related to race, age, tumor subtype, and grade.Impact:Given higher mortality among Black and young women, more defined immune classification using cell-type–specific panels could help explain higher recurrence and ultimately lead to targetable interventions.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients
Supplementary Figure from The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients
Supplementary Figure from The Landscape of Immune Microenvironments in Racially Diverse Breast Cancer Patients
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Obesity and Breast Cancer Metastasis across Genomic Subtypes
Supplementary Figure from Obesity and Breast Cancer Metastasis across Genomic Subtypes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Obesity and Breast Cancer Metastasis across Genomic Subtypes
Supplementary Figure from Obesity and Breast Cancer Metastasis across Genomic Subtypes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Obesity and Breast Cancer Metastasis across Genomic Subtypes
Supplementary Table from Obesity and Breast Cancer Metastasis across Genomic Subtypes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Obesity and Breast Cancer Metastasis across Genomic Subtypes
Supplementary Table from Obesity and Breast Cancer Metastasis across Genomic Subtypes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Obesity and Breast Cancer Metastasis across Genomic Subtypes
Background:Obese women have higher risk of aggressive breast tumors and distant metastasis. However, obesity has rarely been assessed in association with metastasis in diverse populations.Methods:In the Carolina Breast Cancer Study Phase 3 (2008–2013), waist-to-hip ratio (WHR), body mass index (BMI), and molecular subtype [PAM50 risk-of-recurrence (ROR) score] were assessed. Obesity measures were evaluated in association with metastasis within five years of diagnosis, overall and stratified by race and ROR score. Absolute risk of metastasis and risk differences between strata were calculated using the Kaplan–Meier estimator, adjusted for age, grade, stage, race, and ER status. Relative frequency of metastatic site and multiplicity were estimated in association with obesity using generalized linear models.Results:High-WHR was associated with higher risk of metastasis (5-year risk difference, RD, 4.3%; 95% confidence interval, 2.2–6.5). It was also associated with multiple metastases and metastases at all sites except brain. The 5-year risk of metastasis differed by race (11.2% and 6.9% in Black and non-Black, respectively) and ROR score (19.5% vs. 6.6% in high vs. low-to-intermediate ROR-PT). Non-Black women and those with low-to-intermediate ROR scores had similar risk in high- and low-WHR strata. However, among Black women and those with high ROR, risk of metastasis was elevated among high-WHR (RDBlack/non-Black = 4.6%, RDHigh/Low-Int = 3.1%). Patterns of metastasis were similar by BMI.Conclusions:WHR is associated with metastatic risk, particularly among Black women and those with high-risk tumors.Impact:Understanding how risk factors for metastasis interact may help in tailoring care plans and surveillance among patients with breast cancer.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Obesity and Breast Cancer Metastasis across Genomic Subtypes
Background:Obese women have higher risk of aggressive breast tumors and distant metastasis. However, obesity has rarely been assessed in association with metastasis in diverse populations.Methods:In the Carolina Breast Cancer Study Phase 3 (2008–2013), waist-to-hip ratio (WHR), body mass index (BMI), and molecular subtype [PAM50 risk-of-recurrence (ROR) score] were assessed. Obesity measures were evaluated in association with metastasis within five years of diagnosis, overall and stratified by race and ROR score. Absolute risk of metastasis and risk differences between strata were calculated using the Kaplan–Meier estimator, adjusted for age, grade, stage, race, and ER status. Relative frequency of metastatic site and multiplicity were estimated in association with obesity using generalized linear models.Results:High-WHR was associated with higher risk of metastasis (5-year risk difference, RD, 4.3%; 95% confidence interval, 2.2–6.5). It was also associated with multiple metastases and metastases at all sites except brain. The 5-year risk of metastasis differed by race (11.2% and 6.9% in Black and non-Black, respectively) and ROR score (19.5% vs. 6.6% in high vs. low-to-intermediate ROR-PT). Non-Black women and those with low-to-intermediate ROR scores had similar risk in high- and low-WHR strata. However, among Black women and those with high ROR, risk of metastasis was elevated among high-WHR (RDBlack/non-Black = 4.6%, RDHigh/Low-Int = 3.1%). Patterns of metastasis were similar by BMI.Conclusions:WHR is associated with metastatic risk, particularly among Black women and those with high-risk tumors.Impact:Understanding how risk factors for metastasis interact may help in tailoring care plans and surveillance among patients with breast cancer.
- 4 April 2025
- Published by Kidney Cancer Association (KCA) in Kidney Cancer Journal
- Vol. 23 (1) , 11-18
Body composition, ClearCode34, and survival in localized clear cell renal cell cancer
BACKGROUND: Poor muscle health is an adverse prognostic factor in clear cell renal cell cancer (ccRCC), but mechanisms are unknown. We examined associations among six body composition features, ClearCode34 tumor molecular subtype, and survival. METHODS: In a cohort of 837 patients with localized ccRCC, we segmented pre-surgical CT scans for cross-sectional areas and radiodensities of skeletal muscle, visceral adiposity, and subcutaneous adiposity. RNA was extracted from archived tumor specimens and run on a custom Nanostring array. A centroid- based classification categorized tumors as ccA (less aggressive) or ccB (more aggressive) ClearCode34 subtype. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for associations between body composition and ClearCode34 subtype. Hazard ratios (HRs) and 95% CIs were estimated for individual and joint effects of body composition features and ClearCode34 subtype on 5-year disease-free survival (DFS). RESULTS: The cohort was predominantly male, white, and had Stage I disease; 26% of tumors were ccB subtype. 95 DFS events occurred over 3532.2 person-years of follow-up. Patients with lower skeletal muscle radiodensity (SMD) were more likely to harbor ccB tumors (OR per 10-unit decrease in SMD: 1.30, 95% CI: 1.00-1.69). Exploratory joint effects analyses suggested patients with lower SMD and ccB subtype experienced the lowest DFS compared to patients without those characteristics (HR 2.68, 95% CI: 1.43-5.00). CONCLUSIONS: ccRCC patients with lower SMD (more fat- infiltrated skeletal muscle) at diagnosis may experience worse survival because they harbor more aggressive tumors. Future studies should determine how post-nephrectomy changes in body composition features are associated with survival.
- 4 April 2025
- Published by Kidney Cancer Association (KCA) in Kidney Cancer Journal
- Vol. 23 (1) , 11-18
Body composition, ClearCode34, and survival in localized clear cell renal cell cancer
BACKGROUND: Poor muscle health is an adverse prognostic factor in clear cell renal cell cancer (ccRCC), but mechanisms are unknown. We examined associations among six body composition features, ClearCode34 tumor molecular subtype, and survival. METHODS: In a cohort of 837 patients with localized ccRCC, we segmented pre-surgical CT scans for cross-sectional areas and radiodensities of skeletal muscle, visceral adiposity, and subcutaneous adiposity. RNA was extracted from archived tumor specimens and run on a custom Nanostring array. A centroid- based classification categorized tumors as ccA (less aggressive) or ccB (more aggressive) ClearCode34 subtype. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated for associations between body composition and ClearCode34 subtype. Hazard ratios (HRs) and 95% CIs were estimated for individual and joint effects of body composition features and ClearCode34 subtype on 5-year disease-free survival (DFS). RESULTS: The cohort was predominantly male, white, and had Stage I disease; 26% of tumors were ccB subtype. 95 DFS events occurred over 3532.2 person-years of follow-up. Patients with lower skeletal muscle radiodensity (SMD) were more likely to harbor ccB tumors (OR per 10-unit decrease in SMD: 1.30, 95% CI: 1.00-1.69). Exploratory joint effects analyses suggested patients with lower SMD and ccB subtype experienced the lowest DFS compared to patients without those characteristics (HR 2.68, 95% CI: 1.43-5.00). CONCLUSIONS: ccRCC patients with lower SMD (more fat- infiltrated skeletal muscle) at diagnosis may experience worse survival because they harbor more aggressive tumors. Future studies should determine how post-nephrectomy changes in body composition features are associated with survival.
- Open Access
- 6 January 2025
- Published by Springer Nature in Cancer Causes & Control
- Vol. 36 (5) , 497-507
Pre- and post-diagnosis body weight trajectories in patients with localized renal cell cancer
Purpose: Obesity in mid-life is a well-established risk factor for developing renal cell carcinoma (RCC); however, patients with RCC who are obese at the time of diagnosis have more favorable survival outcomes. To get better insight into the obesity paradox and determine the extent to which weight around diagnosis is stable, we examined pre- and post-diagnosis weight changes in patients with localized RCC. Methods: We included 334 patients with localized RCC from the prospective cohort ReLife who self-reported body weight at multiple time points ranging from 2 years before to 2 years after diagnosis. Multivariable linear mixed-effects regression models were used to compare weight at each timepoint to weight at diagnosis for the overall study population, as well as stratified by BMI at diagnosis, tumor stage, and tumor grade. Results: Most patients were classified as overweight (38.3%) or obese (29.6%) at diagnosis. Overall, patients experienced on average 1.45 kg (95% confidence interval (CI) 0.84, 2.06) weight loss in the 2 years before diagnosis. Pre-diagnosis weight loss was higher in patients who were non-obese at diagnosis, and who presented with higher tumor stage and grade. On average, pre-diagnosis weight loss was at least partially regained within two years after diagnosis. Conclusion: Patients who were non-obese and patients with higher stage and grade tumors had higher pre-diagnosis weight loss, which was at least partially regained after treatment. These patterns suggest there are subgroups of patients with localized RCC who experience disease-related weight loss, which could contribute to the obesity paradox.
- 6 January 2025
- Published by Springer Nature in Cancer Causes & Control
- Vol. 36 (5) , 497-507
Open AccessPre- and post-diagnosis body weight trajectories in patients with localized renal cell cancer
Purpose: Obesity in mid-life is a well-established risk factor for developing renal cell carcinoma (RCC); however, patients with RCC who are obese at the time of diagnosis have more favorable survival outcomes. To get better insight into the obesity paradox and determine the extent to which weight around diagnosis is stable, we examined pre- and post-diagnosis weight changes in patients with localized RCC. Methods: We included 334 patients with localized RCC from the prospective cohort ReLife who self-reported body weight at multiple time points ranging from 2 years before to 2 years after diagnosis. Multivariable linear mixed-effects regression models were used to compare weight at each timepoint to weight at diagnosis for the overall study population, as well as stratified by BMI at diagnosis, tumor stage, and tumor grade. Results: Most patients were classified as overweight (38.3%) or obese (29.6%) at diagnosis. Overall, patients experienced on average 1.45 kg (95% confidence interval (CI) 0.84, 2.06) weight loss in the 2 years before diagnosis. Pre-diagnosis weight loss was higher in patients who were non-obese at diagnosis, and who presented with higher tumor stage and grade. On average, pre-diagnosis weight loss was at least partially regained within two years after diagnosis. Conclusion: Patients who were non-obese and patients with higher stage and grade tumors had higher pre-diagnosis weight loss, which was at least partially regained after treatment. These patterns suggest there are subgroups of patients with localized RCC who experience disease-related weight loss, which could contribute to the obesity paradox.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Supplementary Table S7. Hazard ratios and 95% confidence intervals for associations between immune cell types and risk of prostate cancer progression in the UNC CSC, overall and stratified by ERG expression.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Supplementary Table S7. Hazard ratios and 95% confidence intervals for associations between immune cell types and risk of prostate cancer progression in the UNC CSC, overall and stratified by ERG expression.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Supplementary Figure S1. Correlation plot for the relationship of gene expression-based with histological measures of immune infiltrate in prostate cancer. Gene expression-based measures include B cells, T cells, Th cells, Tfh, Treg, exhausted CD4 T cells, CD8 T cells, exhausted CD8 T cells, NK cells, neutrophils, eosinophils, macrophages and immune signature. Histological measures include TILs% tumor gland, TILs% tumor stroma and neutrophils grade tumor. Spearman’s correlation. *P < 0.05, **P < 0.01, ***P < 0.001. TILs, tumor infiltrating lymphocytes.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Supplementary Figure S1. Correlation plot for the relationship of gene expression-based with histological measures of immune infiltrate in prostate cancer. Gene expression-based measures include B cells, T cells, Th cells, Tfh, Treg, exhausted CD4 T cells, CD8 T cells, exhausted CD8 T cells, NK cells, neutrophils, eosinophils, macrophages and immune signature. Histological measures include TILs% tumor gland, TILs% tumor stroma and neutrophils grade tumor. Spearman’s correlation. *P < 0.05, **P < 0.01, ***P < 0.001. TILs, tumor infiltrating lymphocytes.
- Open Access
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Supplementary Table S8. Hazard ratios and 95% confidence intervals for associations between immune cell types and risk of prostate cancer progression in the FASTMAN, overall and stratified by ERG expression.
- 2 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Supplementary Table S8. Hazard ratios and 95% confidence intervals for associations between immune cell types and risk of prostate cancer progression in the FASTMAN, overall and stratified by ERG expression.